Opdivo Lung Cancer Approval Holds Lessons For Competitors
Bristol is required to run a new study assessing the risk for pneumonitis, but analysts do not see the adverse event as a competitive threat. FDA showed significant flexibility with broad, fast approval, but Opdivo’s survival advantage may raise the bar for the rest of the class.
You may also be interested in...
Lung cancer wasn’t viewed traditionally as a tumor that would respond to immunotherapy. But with checkpoint inhibitor data looking promising, big pharma is diving in and prioritizing the disease, reeled in by the large patient population and high unmet need.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.